Vincent M Isabella

This inventor holds 25 USPTO granted patents and 26 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Engineered Microorganisms. Top assignees: Synlogic Operating Company, Inc., Synlogic, Inc., Ginkgo Bioworks, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vincent M Isabella. Retrieved from https://idiyas.com/inventor/vincent-m-isabella

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 26)

% Patents Active = 92.0

CIPO Patents = 1 (Patent Applications = 14)

EPO Patents = 6 (Patent Applications = 29)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 123(Granted Patents)

Location History:

Cambridge, MA (US) (2016 - 2023)
Watertown, MA (US) (2022 - 2023)
Medford, MA (US) (2021 - 2024)

Company Filing History:

21 out of 24

Synlogic Operating Company, Inc.

Ginkgo Bioworks, Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Engineered Microorganisms

Bacteria

Metabolic Diseases

Gut Inflammation

Cancer Therapeutics

Hyperphenylalaninemia

Hyperammonemia

Immune Modulators

Liver Disease

Tumor Cells

Disorders

Recombinant Bacteria

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703866 - ENGINEERED MICROORGANISMS (2026-08-11),

2. 12545886 - BACTERIA FOR THE TREATMENT OF DISORDERS (2026-02-10),

3. 12409195 - Bacteria engineered to reduce hyperphenylalaninemia (2025-09-09),

4. 11896627 - Bacteria engineered to treat metabolic diseases (2024-02-13),

5. 11883439 - Bacteria engineered to treat a disease or disorder (2024-01-30),

6. 11879123 - Bacteria for the treatment of disorders (2024-01-23),

7. 11859189 - Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof (2024-01-02),

8. 11845964 - Bacteria engineered to treat diseases associated with hyperammonemia (2023-12-19),

9. 11723932 - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells (2023-08-15),

10. 11685925 - Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier (2023-06-27),

11. 11618894 - Bacteria engineered to reduce hyperphenylalaninemia (2023-04-04),

12. 11471494 - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells (2022-10-18),

13. 11439673 - Bacteria engineered to treat liver disease (2022-09-13),

14. 11384359 - Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier (2022-07-12),

15. 11291693 - Bacteria engineered to treat metabolic diseases (2022-04-05),

Title: The Innovative Journey of Vincent M Isabella

Introduction: Vincent M Isabella is a renowned inventor based in Cambridge, MA, known for his groundbreaking contributions to various fields.

Latest Patents: Vincent M Isabella holds several patents in the areas of technology and healthcare, showcasing his continuous innovation and dedication to improving industries.

Career Highlights: With a career spanning over two decades, Vincent M Isabella has worked with leading research institutions and companies, developing cutting-edge solutions that have revolutionized the way we approach challenges.

Collaborations: Throughout his career, Vincent M Isabella has collaborated with top universities, research institutions, and companies, fostering a culture of innovation and knowledge-sharing that has led to remarkable advancements in the industry.

Conclusion: Vincent M Isabella's passion for innovation and his relentless pursuit of excellence have solidified his position as a pioneering inventor, shaping the future of technology and beyond.

Profile summary based on public USPTO records.